Investor Presentaiton

Screening Early Disease Detection Minimal Residual Disease Recurrence Detection & Surveillance Therapy Selection Advanced Cancer Care >120M Average-Risk Individuals shield™ GUARDANT™ Cancer Detection >15M Early-Stage Patients and Survivors Surgery +/- Adjuvant GUARDANTREVEAL Recurrence >700K Advanced Cancer Patients INVESTOR 20 DAY 23 1st Line Tx 2nd Line Tx +TX FDA Approved GUARDANT 360CDX GUARDANT 360 GUARDANT 360 TissueNext GUARDANT 360 Response 13

View entire presentation